M.F. and F.M. contributed equally to this study.
Summary
The inherited thrombocytopenias (IT) are a heterogeneous group of diseases resulting from mutations in more than 30 different genes. Among them, ACTN1-related thrombocytopenia (ACTN1-RT; Online Mendelian Inheritance in Man: 615193) is one of the most recently identified forms. It has been described as a mild autosomal dominant macrothrombocytopenia caused by mutations in ACTN1, a gene encoding for one of the two nonmuscle isoforms of a-actinin. We recently identified seven new unrelated families with ACTN1-RT caused by different mutations. Two of them are novel missense variants (p.Trp128Cys and p.Pro233Leu), whose pathogenic role has been confirmed by in vitro studies. Together with the 10 families we have previously described, our cohort of ACTN1-RT now consists of 49 individuals carrying ACTN1 mutations. This is the largest case series ever collected and enabled a critical evaluation of the clinical aspects of the disease. We concluded that ACTN1-RT is the fourth most frequent form of IT worldwide and it is characterized by platelet macrocytosis in all affected subjects and mild thrombocytopenia in less than 80% of cases. The risk of bleeding, either spontaneous or upon haemostatic challenge, is negligible and there are no other associated defects, either congenital or acquired. Therefore, ACTN1-RT is a benign form of IT, whose diagnosis provides affected individuals and their families with a good prognosis.
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At the end of the last century a few forms of inherited thrombocytopenias (ITs) had been recognized thanks to their phenotypic characteristics. Clinical studies were the basis for identification of new disorders and their clinical features were, therefore, well-defined as soon as the disease-causing gene was identified. The introduction of new and effective gene sequencing techniques and their recent application to case series of subjects with unknown ITs greatly increased the number of genes whose mutations are responsible for thrombocytopenia. At present, more than 30 different forms are known, whose molecular mechanisms have been determined in many cases (Savoia, 2016; Balduini et al, 2017) .
However, the clinical picture associated with the genes recently identified is not always well-defined because the clinical characteristics of patients are not available or the number of investigated subjects is limited. This is the case in ACTN1-related thrombocytopenia (ACTN1-RT; Online Mendelian Inheritance in Man: 615193), which is caused by heterozygous mutations in ACTN1, a gene encoding one of the two non-muscle isoforms of a-actinin, which is mainly expressed in megakaryocytes and platelets (Haudek et al, 2009 ). Indeed, seven independent studies have identified different variants of ACTN1 in 44 unrelated families (Gu eguen et al, 2013; Kunishima et al, 2013; Bottega et al, 2015; Westbury et al, 2015; Johnson et al, 2016; Yasutomi et al, 2016; Boutroux et al, 2017) .
a-Actinin contains an actin binding region comprising two calponin homology (CH) domains at the N-terminus, four spectrin repeats and a calmodulin-like motif (CaM) (Otey & Carpen, 2004; Sj€ oblom et al, 2008) . Antiparallel molecules dimerize in rod-like structures with the actin binding domain at each extremity for cross-linking the actin filaments into bundles. Dimers of ACTN1 cross-link actin filaments, which interact with myosins and generate contractile forces. Although the exact role of ACTN1 in platelet biogenesis is poorly known, the observation that mouse megakaryocytes expressing ACTN1 variants cause defective proplatelet extension supports the hypothesis that this molecule is important for the final phases of platelet production (Kunishima et al, 2013) .
Screening for mutations in 130 unrelated probands with IT, we identified seven ACTN1 variants. Three were novel missense variants, whose pathogenic effect was demonstrated only for two. This allowed us to study 18 new patients from seven unrelated families suffering from ACTN1-RT, who, together with those previously reported by us represent a cohort of 49 patients (Bottega et al, 2015) . Critical analysis of this large case series, as well as of the data reported in the literature, enabled us to propose a reliable clinical picture of ACTN1-RT.
Materials and methods

Patients
One hundred and thirty consecutive, unrelated patients with IT who were observed at the IRCCS Policlinico San Matteo Foundation of Pavia, Italy, were enrolled in the study. All of these patients had no definite diagnosis because they did not fit the criteria for any known disorder. Whenever ACTN1 mutations were identified, the proband's available relatives were studied. Information on medical history (including family history), bleeding tendency and outcome of possible surgeries and pregnancies were obtained from medical records or patients' interviews. Bleeding tendency was measured by the World Health Organization bleeding scale: grade 0 indicates no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; and grade 4, debilitating blood loss. The institutional review boards of the IRCCS Policlinico San Matteo Foundation of Pavia approved the study. All subjects provided written informed consent in accordance with the Declaration of Helsinki.
Mutational screening
Genomic DNA extracted from peripheral blood was used to screen for the ACTN1 gene. Mutational analysis was performed by whole exome sequencing (WES) or by target next generation sequencing (NGS) of 22 IT genes as previously reported (Marconi et al, 2016; Nicchia et al, 2016) . Variants were confirmed by Sanger sequencing.
Immunofluorescence analysis
A full-length ACTN1 sequence was amplified from normal platelet cDNA and constructed into the pcDNA3Á1-Myc tagged expression vector as previously described (Bottega et al, 2015) . Three ACTN1 variants (c.384G>C/p.Trp128Cys, c.698C>T/p.Pro233Leu and c.2210C>G/p.Thr737Ser) were generated by directed mutagenesis using specific mutagenesis primers designed with the mutations (available upon request). For immunofluorescence assay, Chinese hamster ovary (CHO) cells were seeded on chamber slides and transfected with Myc-tagged wild type or mutated ACTN1 plasmids. After 16 h, cells were fixed with 4% paraformaldehyde for 20 min and then permeabilized with 0Á1% Triton X-100. For detection of ACTN1, primary antibody against c-myc (also termed MYC) (9E10; Santa Cruz Biotechnology, Dallas, TX, USA) was used with anti-mouse fluorescein isothiocycante (FITC) secondary antibody (F0479; DakoCytomation; Glostrup, Denmark), while actin filaments were stained with AlexaFluor594-conjugated phalloidin (Invitrogen, Marseille, France). Images were obtained with a Nikon C1si confocal microscope (Nikon, Shinjuku, Japan), fitted with a 488 nm argon laser line and 561 nm diode laser. Images were processed for z-projection (maximum intensity), brightness and contrast regulation using ImageJ 1Á45 (NIH, Bethesda, USA).
Blood cell studies
Blood cell counts were evaluated by electronic counters. In some cases, platelet count was also measured by manual platelet counting with optical microscopy in a Neubauer chamber. Platelet diameters were measured by software-assisted image analysis, as reported (Noris et al, 2014) , on MayGr€ unwald-Giemsa stained blood films obtained by finger prick. The following parameters were computed: mean platelet diameter (MPD); platelet diameter distribution width (PDDW), as the 97Á5th to 2Á5th percentiles difference; platelet diameter large cell ratio (PDLCR), as the mean percentage of platelets above the 97Á5th percentile of platelet diameter distribution in controls; and platelet diameter small cell ratio (PDSCR), as the mean percentage of platelets below the 2Á5th percentile of platelet diameter distribution in controls (Noris et al, 2014) .
Surface expression of platelet glycoproteins (GPs) was investigated by flow cytometry as previously reported (Noris et al, 2006) . The following monoclonal antibodies were used: SZ2 (Immunotech, Marseille, France) and MB45 (CLB, Amsterdam, the Netherlands), which bind GPIba (CD42b); SZ1 (Immunotech), which binds GPIX (CD42a); ACTN1-Related Thrombocytopenia ª 2018 British Society for Haematology and John Wiley & Sons Ltd SZ21 (Immunotech), which binds GPIIIa (b3/CD61); P2 (Immunotech), which binds GPIIb (aIIb) when it is correctly complexed with GPIIIa. MO2, used as a negative control, and a FITC-conjugated goat anti-mouse IgG were purchased from Coulter Corporation, (Miami, FL, USA). Fluorescent antibody staining of the platelets was analysed with the FC500 flow cytometer (Beckman Coulter, Brea, CA, USA). Results were expressed as percentage of mean fluorescence intensity with respect to a control run in parallel.
Platelet aggregation was measured in platelet rich plasma by the densitometric method of Born, as reported by Noris et al (2006) . Platelets were stimulated with collagen (4 lg/ ml) (Mascia Brunelli, Milan, Italy), adenosine diphosphate (5 mmol/l, Sigma-Aldrich, St. Louis, MO, USA) or ristocetin (1Á5 mg/ml, Sigma-Aldrich). The extent of platelet aggregation was measured 5 min after the addition of the stimulating agents.
Results
Identification of novel ACTN1 variants
In order to search for mutations in our case series of patients affected by an IT of unknown origin, we applied a NGS approach, using both WES (89 probands) and a target panel of 22 IT genes (41 probands). We identified 7 variants of the ACTN1 gene in 8 probands. Of these variants, four (c.136C>T/p.Arg46Trp, c.313G>A/p.Val105Ile, c.673G>A/ p.Glu225Lys and c.2255G>A/p.Arg752Gln) were mutations already known to be associated with ACTN1-RT ( Table I) . The remaining three variants (c.384G>C/p.Trp128Cys, c.698C>T/p.Pro233Leu and c.2210C>G/p.Thr737Ser) were novel amino acid substitutions (Fig 1) . The latter affects the same Thr737 amino acid residue as c.2010C>A (p.Thr737Asn), a previously-identified ACTN1 mutation (Bottega et al, 2015) .
Pathogenicity prediction of variants
The residues affected by the three novel variants are well conserved throughout evolution (PhyloP100 ranging from 7Á858 and 9Á968). The Combined Annotation Dependent Depletion (CADD) scores were high: 34 for p.Trp128Cys and p.Pro233Leu and 22Á6 for p.Thr737Ser. Consistent with this, other bioinformatics tools predict a higher impact of p.Trp128Cys and p.Pro233Leu than p.Thr737Ser on protein function (Table I) .
Moreover, mapping the seven mutations identified onto the structure of the acting binding motif [Protein Data Bank (PDB; https://www.rcsb.org/) code 2eyi] we rationalized their effects on the protein (Fig 2) . Arg46 sits right at the end of helix1 and points directly towards Asp217 from the second CH motif, forming a salt bridge. This is predicted to stabilize the structure and keep the mutual orientation of the two CH domains. Substitution with a Trp would have profound influence on the structure stability. Val105 is buried inside the hydrophobic core (accessible surface area 0 A 2 ) and tightly packs against the spatially-nearby Thr129 and Ile130 residues. Replacement of Val with an Ile would produce a clash and therefore, again, destabilization. Glu225 is at the very beginning of a helix and is completely exposed (accessible surface area 139 A 2 ). Because it does not form any intracellular salt bridge or distal contact, it is difficult to predict what its substitution could produce. However, a reasonable hypothesis is that it takes part in interactions with actin. Of the two newly identified mutations in the CH motif, Trp128 is semi-buried (accessible surface area 32 A 2 ) and packs against Thr240, with Lys236 forming stacking against the aromatic ring. Substitution with a smaller Cys would destabilize the fold, creating a cavity. It could also promote intermolecular cross-linking and aggregation. Finally, Pro233 is in a loop between two helices, is buried (accessible surface area 0 A 2 ) and packs tightly against the hairpin containing His170 and Ile171. Replacement of Pro with the bulkier Leu would produce a clash and perturb the loop structure.
Understanding the effect of the mutations in the C-terminal calmodulin-like motif is more difficult. Residue Arg752 is in helix E (the first helix of the first EF-hand) and is completely exposed to the solvent (Fig 2C) . Considering that it does not form salt bridges or other specific interactions with the environment, mutations of this sort would result in disruption of interactions with other cellular partners. Finally, the novel p.Thr737Ser affects a residue that is not part of the nuclear magnetic resonance (NMR) structure of this domain in its non-calcium bound form (PDB code 2n8y), preventing the comprehension of the effects on protein function or stability.
p.Trp128Cys and p.Pro233Leu but not p.Thr737Ser lead to cytoskeleton disorganization
We performed immunofluorescence analyses on the wild type and mutant forms of ACTN1 transiently overexpressed in a CHO cell line to confirm the pathogenic role of p.Trp128Cys, p.Pro233Leu and p.Thr737Ser (Fig 4) . When cells were transfected with the wild type construct, ACTN1 co-localized with actin along filaments in a well-organized cytoskeleton. Of note, the same result was obtained when we transfected cells with the p.Thr737Ser mutant form of ACTN1. In contrast, cells transfected with p.Trp128Cys and p.Pro233Leu, as well as p.Thr737Asn constructs and stained with phalloidin, showed altered distribution of actin, which was not organized in filaments, causing an evident disruption in the cytoskeletal structure. Moreover, as shown through the anti-Myc antibodies, the mutant ACTN1 molecules do not colocalize with actin and were uniformly distributed within the cytoplasm. T, tolerated; D, damaging; B, benign; M, medium; L, low; H, high; nr, not reported.
*Nucleotide A of the ATG translation initiation start site of the ACTN1 gene cDNA in GenBank sequence NM_001130004Á1 is indicated as nucleotide +1. †Affecting the same amino acid as c.2210C>A/p.Thr737Asn (Bottega et al, 2015) . The pathogenic prediction for p.Thr737Asn is also reported (grey row).
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Segregation analysis
To confirm the functional data obtained by the immunofluorescence studies, we carried out segregation analysis when biological samples were available. The p.Trp128Cys variant segregated with thrombocytopenia in four affected members of Family 3 (Fig 1) . However, the patient heterozygous for p.Thr737Ser has inherited the variant from his mother, whose platelet count was in the normal range (203 9 10 9 /l).
Clinical features
Six of the seven families with pathogenic variants in ACTN1 were from Italy, while one was a Finnish family. Of the 18 affected family members, 11 were females and 7 were males (Table II) . Family history studies identified 22 additional family members, dead or not available for this study, with low platelet count revealed on one or more occasions. In all the propositi, thrombocytopenia was discovered incidentally when blood counts were performed for reasons other than bleeding tendency. Initially, one patient received a diagnosis of immune thrombocytopenia without receiving any treatment due to his mild thrombocytopenia. Bleeding tendency was absent in 13 subjects and very mild in 5, consisting of rare nosebleeds and easy bruising. Eleven patients underwent one or more surgical or other invasive procedures without any prophylactic treatment and no excessive blood loss was reported. Six women gave birth to 13 children (9 vaginal deliveries and 4 caesarean sections) without excessive bleeding. Only one delivery was covered by platelet transfusion.
History and examination of patients did not reveal any congenital or acquired phenotypic defect consistently associated with ACTN1 mutations.
Blood cell counts and peripheral blood film examination
Haemoglobin and leucocyte values were within the normal range in all cases (data not shown). Interestingly, platelet count was reduced in most, but not all, cases. In fact, using the traditional lower limit of normal platelet count (150 9 10 9 /l), two individuals were not thrombocytopenic (Table III) , while the number of subjects with a normal platelet count increased to 4 (22% of cases) using the reference range personalized for age and gender recently proposed for the Italian population (Biino et al, 2013) . No genotype-phenotype correlation was found concerning the occurrence of thrombocytopenia. When present, thrombocytopenia was mild to moderate and no subject had a platelet count less than 70 9 10 9 /l, while only 7 out of 18 patients had a platelet count less than 100 9 10 9 /l (Table III) . Of note, in all the 7 subjects whose platelet count was evaluated by both cell counter and manual counting, we observed an underestimation of the platelet count through the electronic instrument (Table III) . This phenomenon is typical of macrothrombocytopenias, because electronic counters do not recognize very large platelets (Noris et al, 2013) . This also alters the MPV evaluation. In fact, measuring the platelet diameters by image analysis on blood smears we observed an increased platelet size in all cases, including three cases with normal MPV reported by the electronic counter. Mapping the mutations onto the a-actinin1 structure. (A) Modular architecture of the protein as produced by the SMART EMBL web server (http://smart.embl-heidelberg.de/) and position of mutations reported in this paper. The protein is organized into an acting binding domain constituted of two calponin homology (CH) domains at the N-terminus, four spectrin (SPEC) motifs, and a calmodulin-like motif (CaM) with two calcium binding EF-hands (EFh) and two degenerate calcium insensitive EF-hands (efhand Ca_insen) at the C-terminus. (B) Two views differing by a -90-degree rotation around the x axis of the backbone atoms in the structure of the tandem CH domains from the human actinin-1 isoform (Protein Data Bank [PDB] code 2eyi). The side chains of the residues corresponding to those observed in the point missense mutations are explicitly indicated. Previously described mutations are indicated in green, the two positions of the newly described mutants are indicated in blue and the side chains of neighbouring residues which might be affected by the mutations are indicated in red. Measurement of PDDW revealed that another constant feature of the investigated subjects was platelet anisocytosis due to the presence of a high proportion of large platelets (PDLCR higher than normal in all cases). The percentage of small platelets was instead reduced or normal. Based on these findings, the only blood cell abnormality found in all patients was platelet macrocytosis with anisocytosis. Of note, careful evaluation of blood films revealed that all subjects with ACTN1 mutations had platelet poikilocytosis due to the presence of elongated, often curved elements that sometimes closely resembled the proplatelets released in vitro by cultured human megakaryocytes (Fig 3) (Thon et al, 2010) . These proplatelet-like structures were not identified in the subject with the p.Thr737Ser variant. However, we cannot conclude that their presence in blood films is unique to ACTN1-RT, because no systematic search of these elements has been performed in other congenital or acquired forms of thrombocytopenia.
Platelet aggregation and flow cytometry
In vitro platelet aggregation and platelet flow cytometry of the major platelet glycoproteins were performed in 10 of 18 patients. The maximal extent of platelet aggregation after collagen, ADP and ristocetin stimulation was within the normal range of our laboratory. Components of the GPIb/IX/V and GPIIb/IIIa complexes were not reduced in any patient with respect to controls run in parallel. In a few cases they were increased by more than 20% due to the presence of large platelets.
Discussion
As a result of recent advances, the number of known ITs is increasing rapidly and this chapter of haematology becomes very complex due to the great variability of clinical symptoms and prognosis of affected subjects . Some ITs, such as Wiskott-Aldrich syndrome, congenital amegakaryocytic thrombocytopenia and PRKACG-related thrombocytopenia, are typically characterized by very low platelet counts and severe bleeding tendency. Others, such as the biallelic Bernard-Soulier syndrome (BSS), have a bleeding risk much higher than expected on the basis of platelet count due to an associated severe defect of platelet function, while many ITs, such as TUBB1-and CYCS-related thrombocytopenia, have mild thrombocytopenia and mild bleeding tendency, or even no bleeding tendency at all. Many ITs, e.g. thrombocytopenia-absent radius syndrome and WiskottAldrich syndrome, have additional congenital defects associated with thrombocytopenia, while many other forms are not syndromic. Finally, some mutations increase the risk of acquiring additional defects that endanger patients' life much more than the low platelet count. This is the case of mutations in RUNX1, ANKRD26 and ETV6, which expose patients to the risk of haematological malignancies, MYH9, which predisposes to kidney failure, or in MPL and THPO, which cause acquired bone marrow aplasia .
The clinical approach to patients with ITs must take all these variables into account when designing personalized follow-up regimens, providing appropriate genetic counselling within the normal range of the laboratory §N: normal, i.e. mean florescence intensity no more than 20% higher or lower with respect to a control run in parallel; I: increased, i.e. mean florescence intensity 20% higher than 20% with respect to control; na= not available. Platelet counts in bold and underlined are within the normal range of platelet count personalized for age and gender recently proposed for the Italian population (Biino et al, 2013) .
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and, when required, administering effective treatments. However, the clinical characteristics of many recently identified ITs are poorly defined and this hampers personalized management of affected subjects. ACTN1-RT is a form of IT described for the first time in 2013 in six families (Kunishima et al, 2013) . Subsequently, five other groups reported 28 additional families (Gu eguen et al, 2013; Westbury et al, 2015; Johnson et al, 2016; Yasutomi et al, 2016; Boutroux et al, 2017) , but patients were not studied homogeneously, and full clinical-laboratory characteristics were not always described. We have previously reported 10 families including 31 affected individuals (Bottega et al, 2015) . Together with the 18 subjects from the 7 families of this study, our case series consists of 49 patients from 17 families homogeneously investigated, which enabled us to define the clinical features of this condition.
This work allows us to establish the relative frequency of ACTN1-RT. Our database includes 303 consecutive families with ITs. A definite diagnosis was made in 160 cases (including those reported in this paper), while the remaining pedigrees did not fit the criteria for any known disorder. Thus, at least in our experience, ACTN1 mutations were responsible Thr737Asn mutation has also been tested to compare its effect on the cytoskeleton distribution with p.Thr738Ser. The subcellular localization of the over-expressed a-actinin1 (green) was examined using a c-Myc antibody while the actin filaments were stained with phalloidin (red). Cells transfected with the wild type or p.Thr737Ser construct show a well-organized cytoskeleton with ACTN1 co-localizing with actin filaments. In cells expressing the p.Trp128Cys, p.Pro233Leu, and p.Thr737Asn forms of ACTN1 the cytoskeleton is disorganized showing altered distribution of actin. The cells shown are representative of three independent experiments. Scale bar, 10 lm. (B) Localization of 26 mutations reported so far in ACTN1 (Gu eguen et al, 2013; Kunishima et al, 2013; Bottega et al, 2015; Westbury et al, 2015; Johnson et al, 2016; Yasutomi et al, 2016; Boutroux et al, 2017) . The novel mutations described in this paper are in red. Pathogenicity of mutations in bold is supported by in vitro functional studies (Kunishima et al, 2013; Bottega et al, 2015; Yasutomi et al, 2016) . For mutations in regular font, the pathogenic effect is based on bioinformatics prediction (Westbury et al, 2015; Johnson et al, 2016; Boutroux et al, 2017) . Variants of uncertain significance are in italics (Westbury et al, 2015) . CH, calponin homology domain; SPEC, spectrin motif; EFh, calcium binding EF-hand; efhand, calcium insensitive EF-hand (Fig. 2) . for thrombocytopenia in 10Á6% of families with known diagnosis and 5Á6% of all IT families. These data indicate that ACTN1-RT is the fifth most frequent form of IT in Italy, after the monoallelic form of BSS (21Á9% of families with known disorders), MYH9-RD (19Á4%), ANKRD26-RT (15%) and biallelic BSS (12Á5%). Given that the large majority of our patients with monoallelic BSS have the p.A156V variant of GPIba, which is exclusive to the Italian population (Noris et al, 2012) , ACTN1-RT is expected to be the fourth most frequent form of IT worldwide.
Our cohort confirms and extends the concept that ACTN1-RT is a mild bleeding disorder. Bleeding tendency, both spontaneous and in the event of haemostatic challenge, was absent or, at most, mild in all cases. Accordingly, platelet count was only slightly reduced, with the majority of patients presenting with a platelet count between 100 9 10 9 /l and 150 9 10 9 /l. Interestingly, using the platelet count reference range personalized for gender and age recently proposed for the Italian population (Biino et al, 2013) , 4 out of the 18 subjects investigated in this study had normal platelet counts.
On this basis, we re-evaluated our previous case series and found that 6 of 31 subjects had a normal platelet count (Bottega et al, 2015) . Therefore, considering our 49 patients with ACTN1 mutations, more than 20% of the carriers has normal platelet counts. We cannot explain this incomplete penetrance, though we could hypothesize that the ACTN1 mutations exert a mild effect on platelet production, as supported by the moderate thrombocytopenia observed in ACTN1-RT (mean platelet count 102 9 10 9 /l in our cohort).
Thus, at variance with most of the other dominant forms of IT, recognition of the type of disease transmission can be difficult based on platelet count. On the contrary, macrocytosis and anisocytosis of platelets were present in all the affected individuals, and these abnormalities were the only constant phenotypic consequence of the ACTN1 mutations. Thus, we can conclude that ACTN1-RT is characterized by variable expressivity with increased platelet size and anisocytosis in all the individuals carrying a mutation of ACTN1, and thrombocytopenia in less than 80% of cases. In our cohort, the ACTN1 mutations are not associated with other congenital defects. Importantly, they do not predispose the acquisition of any additional disorder during life, in accordance with the literature (Gu eguen et al, 2013; Kunishima et al, 2013; Yasutomi et al, 2016; Boutroux et al, 2017) . Therefore, ACTN1-RT should be regarded as a benign form of IT, whose diagnostic suspicion is supported by the presence of platelet macrocytosis and anisocytosis, bearing in mind that its autosomal dominant transmission can be hidden by incomplete penetrance for thrombocytopenia.
a-Actinin is a relatively well-characterized modular protein. Together with the two novel mutations described here, 26 ACTN1 amino acid substitutions have been associated with thrombocytopenia (Gu eguen et al, 2013; Kunishima et al, 2013; Bottega et al, 2015; Westbury et al, 2015; Johnson et al, 2016; Yasutomi et al, 2016; Boutroux et al, 2017) .
The newly described mutations cluster either at the N-terminus of a-actinin 1 in the two CH motifs, which are responsible for actin binding, or at the C-terminus in the region preceding the calmodulin-like motif or at its interface with the rest of the protein. Of note are mutational hotspots, with 8 variants accounting for 65% of the ACTN1-RT families. In particular, residue Arg46, which can be substituted by Trp or Gln, is the most frequently affected amino acid, being reported in 13 families from different populations, while variants affecting Glu225, Arg738 and Arg752 have been found in 5, 7 and 4 families, respectively. Only 5 variants affect the spectrin motifs within the rod domain even though it encompasses half of the actinin protein sequence (Westbury et al, 2015; Yasutomi et al, 2016) . Of note, there is no correlation between the a-actinin 1 regions affected by mutations and the extent of thrombocytopenia, suggesting that the mutant proteins exert the same pathogenic effect on thrombopoiesis regardless of which domain is altered.
Given that the actin binding and the CH domains are responsible for interaction with actin, alterations of a-actinin 1 are likely to impair the actin filament organization. It has been recently reported that some of these mutant forms exert a gain-of-function effect, resulting in an increased binding to actin, which is likely to affect its filament dynamics (Murphy et al, 2016) . Indeed, the cytoskeleton structure is defective in cells expressing 15 out of the 26 variants identified in the ACTN1 gene, including the two novel mutations p.Trp128Cys and p.Pro233Leu of this paper (Fig 4) (Kunishima et al, 2013; Bottega et al, 2015; Yasutomi et al, 2016) . Nine of the ACTN1 variants have been reported as mutations for their deleterious effect predicted by bioinformatics tools and/or segregation analysis (Westbury et al, 2015; Johnson et al, 2016; Boutroux et al, 2017) . The remaining two amino acid substitutions are considered variants of uncertain significance (Westbury et al, 2015) .
In the light of the data reported in this study, it is of fundamental importance to test the effect of variants on protein function. Indeed, using an immunofluorescence assay, we could conclude that p.Trp128Cys and p.Pro233Leu are two novel mutations of ACTN1, which is consistent with bioinformatics prediction and/or segregation analysis. Like another two missense substitutions (p.Arg197Trp and p.Asp666Val) (Kunishima et al, 2013; Bottega et al, 2015) , p.Thr737Ser should instead be regarded as a very rare 'neutral' variant of ACTN1, as eventually supported by segregation analysis.
Although these data suggest that the ACTN1 mutants alter the cytoskeleton organization, the molecular mechanisms leading to the platelet defects observed in ACTN1-RT are not yet clear. Low young platelet count and only slightly increased serum thrombopoietin levels indicated that thrombocytopenia derives from defects of the final phases of megakaryocyte maturation (Bottega et al, 2015) . Consistent with this conclusion, megakaryocytes from mice expressing mutant forms of ACTN1 extended proplatelets but their tips were reduced in number and increased in size, suggesting a defect in the late phase of proplatelet formation (Kunishima et al, 2013) . Moreover, we observed typical and atypical proplatelets in the blood smears of our patients. Considering that proplatelets are not present in healthy control blood films, probably because of their quick transition to platelets, we hypothesize that defective ACTN1 impairs fission of proplatelets into platelets. Indeed, megakaryocytes generate platelets through the formation of long (up to millimetres in length), thin cytoplasmic extensions that are released into the circulation and eventually transformed into individual platelets. In vitro culture of megakaryocytes revealed that platelet biogenesis requires the formation of preplatelets (discoid giant elements) that have the capacity to convert into barbell-shaped proplatelets and undergo fission into platelets (Thon et al, 2010) . Thus, it is conceivable that the disorganized actin-based cytoskeleton produced in megakaryocytes by ACTN1 variants does not only affect proplatelet extension, as demonstrated by in vitro studies (Kunishima et al, 2013) , but also hampers proplatelet fission into platelets. Whether this defect of platelet formation is exclusive of ACTN1-RT or also occurs in other forms of IT is presently unknown, and, therefore, the diagnostic significance of the presence of proplatelet-like elements in peripheral blood remains undefined.
In conclusion, mutations in ACTN1 cause macrocytosis with anisocytosis of platelets in all affected subjects and mild thrombocytopenia in almost 80% of cases, but they never result in a clinically relevant bleeding tendency. No other defects, either congenital or acquired, have been reported. Therefore, ACTN1-RT is a benign disorder and the most important result of diagnosing this disease is the possibility to reassure affected subjects that their prognosis and their quality of life, as well as those of their progeny, is expected to be very good.
